BioCentury
ARTICLE | Product Development

Warp Speed asking biopharmas to delay seeking EUA until they have enough doses

Operation Warp Speed top adviser Slaoui provides update on COVID-19 vaccine timelines

October 6, 2020 7:46 PM UTC

AstraZeneca could have enough safety and efficacy data late this month to support emergency use authorization of its COVID-19 vaccine, but the company will not start large-scale manufacturing until early 2021, Operation Warp Speed Chief Scientific Adviser Moncef Slaoui said Tuesday. Warp Speed is asking companies developing COVID-19 countermeasures against the novel coronavirus to delay seeking an EUA until they can produce vaccine doses at a commercial scale, Slaoui said Tuesday

Trials of AZD1222 from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford are on hold in the U.S. following reports of adverse events in a U.K. trial, but have been resumed in the U.K., Brazil, South Africa and Japan...